ArticleStroke (Hoboken, N.J.)2024
A Preliminary Study of Anti-TNFα Therapy for Symptomatic Dolichoectatic Vertebrobasilar Aneurysms.
Article in Stroke (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Vertebral Artery Dominance Patterns in Embolic Basilar Artery Occlusion: Insights Toward Embolus Trajectory.Clinical neuroradiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dolichoectatic vertebrobasilar aneurysms (DVBAs) carry high morbidity, and treatment options are limited. The tumor necrosis factor α signaling cascade is implicated in DVBA growth and rupture, but the role of anti-tumor necrosis factor α therapy in DVBA has not been studied. Methods: A retrospective, case-control study of DVBA at a single institution was performed. Two patients with DVBA were treated with infliximab (tumor necrosis factor α inhibitor) as part of routine therapy for rheumatoid arthritis. Three additional patients diagnosed with DVBA were studied as a control group. Routine brain magnetic resonance imaging/magnetic resonance angiography were measured by 2 blinded neuroradiologists to assess DVBA growth. Baseline comorbidities and clinical outcomes were assessed by chart review. Results: The groups were similar with respect to baseline characteristics, and all patients were symptomatic at the time of DVBA diagnosis. One patient who started infliximab during the study period showed a reversal in DVBA growth rate trajectory, with a relative decrease in growth rate by 37% (0.49-0.18 mm Conclusion: This study presents the first investigation of anti-tumor necrosis factor α therapy for DVBA. Infliximab was associated with low and decreasing DVBA growth trajectories with no treatment-related adverse events. The effect of infliximab on clinical outcomes remains uncertain.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.